Saneca Pharmaceuticals

Saneca's price/earnings (P/E) remain unchanged yoy at -5.64 in 2019

By Helgi Analytics - November 24, 2020

Saneca Pharmaceuticals stock traded at EUR 20.3 per share at the end 2019 translating into a market capitalization of USD 22.8 mil. ...

Saneca's ROCE remain unchanged yoy at -9.48% in 2019

By Helgi Analytics - November 25, 2020

Saneca Pharmaceuticals made a net profit of EUR -3.60 mil in 2019, up 0% compared to the previous year. Historically, between ...

Saneca's Total Cash From Operations remain unchanged yoy at EUR -0.519 mil in 2019

By Helgi Analytics - November 24, 2020

Saneca Pharmaceuticals's operating cash flow stood at EUR -0.519 mil in 2019, up 0% when compared to the previous year. ...

Profit Statement 2017 2018 2019
Sales EUR mil 49.2 35.8 57.5
EBITDA EUR mil 0.100 1.76 -1.67
EBIT EUR mil -1.56 0.202 -3.33
Pre-Tax Profit EUR mil -1.66 0.042 -3.60
Net Profit EUR mil -1.50 0 -3.60
Dividends EUR mil 0 0 0
Balance Sheet 2017 2018 2019
Total Assets EUR mil ... 44.8 51.9
Non-Current Assets EUR mil ... 14.2 19.6
Current Assets EUR mil ... 30.2 31.2
Working Capital EUR mil ... 21.8 20.4
Shareholders' Equity EUR mil 25.8 24.3 24.3
Liabilities EUR mil ... 20.4 27.6
Total Debt EUR mil ... 0 9.27
Net Debt EUR mil ... -2.69 8.68
Ratios 2017 2018 2019
ROE % ... 0 -14.8
ROCE % ... 0 -9.48
EBITDA Margin % ... 4.92 -2.90
EBIT Margin % ... 0.565 -5.80
Net Margin % ... 0 -6.26
Net Debt/EBITDA ... -1.52 -5.20
Net Debt/Equity % ... -11.0 35.7
Valuation 2017 2018 2019
Market Capitalisation USD mil ... 23.3 22.8
Enterprise Value (EV) USD mil ... 20.2 32.5
Number Of Shares mil ... 1.00 1.00
Share Price EUR ... 20.3 20.3
EV/EBITDA ... 9.77 -17.2
EV/Sales ... 0.481 0.499
Price/Earnings (P/E) ... ... -5.64
Price/Book Value (P/BV) ... 0.834 0.834
Dividend Yield % ... 0 0

Get all company financials in excel:

Download Sample   $19.99

overview Unit 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
income statement                        
Sales EUR mil 69.7 57.3 48.6 49.2 35.8             ...
EBIT EUR mil 10.1 -0.066 0.134 -1.56 0.202             ...
Net Profit EUR mil 6.60 -1.20 0 -1.50 0             ...
                           
ROE % ... ... ... ... 0             ...
EBIT Margin % ... ... ... ... 0.565             ...
Net Margin % ... ... ... ... 0             ...
balance sheet                        
Total Assets EUR mil ... ... ... ... 44.8             ...
Non-Current Assets EUR mil ... ... ... ... 14.2             ...
Current Assets EUR mil ... ... ... ... 30.2             ...
                           
Shareholders' Equity EUR mil 20.4 27.0 25.8 25.8 24.3             ...
Liabilities EUR mil ... ... ... ... 20.4             ...
Non-Current Liabilities EUR mil ... ... ... ... 11.3             ...
Current Liabilities EUR mil ... ... ... ... 9.06             ...
                           
Net Debt/EBITDA ... ... ... ... -1.52             ...
Net Debt/Equity % ... ... ... ... -11.0             ...
cash flow                        
Total Cash From Operations EUR mil ... ... ... ... ...             ...
Total Cash From Investing EUR mil ... ... ... ... ...             ...
Total Cash From Financing EUR mil ... ... ... ... ...             ...
Net Change In Cash EUR mil ... ... ... ... ...             ...
valuation                        
Market Capitalisation USD mil ... ... ... ... 23.3             ...
Enterprise Value (EV) USD mil ... ... ... ... 20.2             ...
Number Of Shares mil ... ... ... ... 1.00             ...
Share Price EUR ... ... ... ... 20.3             ...
Price/Earnings (P/E) ... ... ... ... ...             ...
Price/Cash Earnings (P/CE) ... ... ... ... 13.0             ...
EV/EBITDA ... ... ... ... 9.77             ...
Price/Book Value (P/BV) ... ... ... ... 0.834             ...
Dividend Yield % ... ... ... ... 0             ...
income statement Unit 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
income statement                        
Sales EUR mil 69.7 57.3 48.6 49.2 35.8             ...
EBITDA EUR mil 13.1 2.50 2.30 0.100 1.76             ...
Depreciation EUR mil 2.97 2.57 2.17 1.66 1.56             ...
EBIT EUR mil 10.1 -0.066 0.134 -1.56 0.202             ...
Net Financing Cost EUR mil ... ... ... 0.003 0.160             ...
Pre-Tax Profit EUR mil ... -1.20 0.056 -1.66 0.042             ...
Tax EUR mil ... 0 0.056 -0.164 0             ...
Net Profit EUR mil 6.60 -1.20 0 -1.50 0             ...
Net Profit Avail. to Common EUR mil 6.60 -1.20 0 -1.50 0             ...
Dividends EUR mil ... 0 0 0 0             ...
growth rates                        
Total Revenue Growth % ... -17.8 -15.2 1.23 -27.2             ...
EBITDA Growth % ... -80.9 -8.00 -95.7 1,663             ...
EBIT Growth % ... -101 -305 0 ...             ...
Pre-Tax Profit Growth % ... ... -105 -3,094 -103             ...
Net Profit Growth % ... -118 -100 ... -100 ...           ...
ratios                        
ROE % ... ... ... ... 0             ...
ROA % ... ... ... ... ...             ...
ROCE % ... ... ... ... 0             ...
EBITDA Margin % ... ... ... ... 4.92             ...
EBIT Margin % ... ... ... ... 0.565             ...
Net Margin % ... ... ... ... 0             ...
Payout Ratio % ... ... ... ... ...             ...
Net Debt/EBITDA ... ... ... ... -1.52             ...
balance sheet Unit 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
balance sheet                        
Cash & Cash Equivalents EUR mil ... ... ... ... 2.69             ...
Receivables EUR mil ... ... ... ... 8.76             ...
Inventories EUR mil ... ... ... ... 18.8             ...
Other ST Assets EUR mil ... ... ... ... 0             ...
Current Assets EUR mil ... ... ... ... 30.2             ...
Property, Plant & Equipment EUR mil ... ... ... ... 14.0             ...
LT Investments & Receivables EUR mil ... ... ... ... 0             ...
Intangible Assets EUR mil ... ... ... ... 0.236             ...
Goodwill EUR mil ... ... ... ... 0             ...
Non-Current Assets EUR mil ... ... ... ... 14.2             ...
Total Assets EUR mil ... ... ... ... 44.8             ...
                           
Trade Payables EUR mil ... ... ... ... 5.77             ...
Short-Term Debt EUR mil ... ... ... ... 0             ...
Other ST Liabilities EUR mil ... ... ... ... 3.29             ...
Current Liabilities EUR mil ... ... ... ... 9.06             ...
Long-Term Debt EUR mil ... ... ... ... 0             ...
Other LT Liabilities EUR mil ... ... ... ... 11.3             ...
Non-Current Liabilities EUR mil ... ... ... ... 11.3             ...
Liabilities EUR mil ... ... ... ... 20.4             ...
Equity Before Minority Interest EUR mil 23.7 23.7 23.7 23.7 23.7             ...
Minority Interest EUR mil 0 0 0 0 0             ...
Equity EUR mil 20.4 27.0 25.8 25.8 24.3             ...
growth rates                        
Total Asset Growth % ... ... ... ... ...             ...
Shareholders' Equity Growth % ... 32.3 -4.44 0 -5.80             ...
Net Debt Growth % ... ... ... ... ...             ...
Total Debt Growth % ... ... ... ... ... ...           ...
ratios                        
Total Debt EUR mil ... ... ... ... 0             ...
Net Debt EUR mil ... ... ... ... -2.69             ...
Working Capital EUR mil ... ... ... ... 21.8             ...
Capital Employed EUR mil ... ... ... ... 36.0             ...
Net Debt/Equity % ... ... ... ... -11.0             ...
Current Ratio ... ... ... ... 3.34             ...
Quick Ratio ... ... ... ... 1.26             ...
cash flow Unit 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
cash flow                        
Net Profit EUR mil 6.60 -1.20 0 -1.50 0             ...
Depreciation EUR mil 2.97 2.57 2.17 1.66 1.56             ...
Non-Cash Items EUR mil ... ... ... ... ...             ...
Change in Working Capital EUR mil ... ... ... ... ...             ...
Total Cash From Operations EUR mil ... ... ... ... ...             ...
                           
Capital Expenditures EUR mil ... ... ... ... ...             ...
Other Investing Activities EUR mil ... ... ... ... ...             ...
Total Cash From Investing EUR mil ... ... ... ... ...             ...
                           
Dividends Paid EUR mil ... ... ... ... ...              
Issuance Of Debt EUR mil ... ... ... ... ...             ...
Total Cash From Financing EUR mil ... ... ... ... ...             ...
                           
Effect of FX Rates EUR mil ... ... ... ... ...             ...
Net Change In Cash EUR mil ... ... ... ... ...             ...
ratios                        
Days Sales Outstanding days ... ... ... ... 89.3             ...
Cash Earnings EUR mil ... ... ... ... 1.56             ...
Free Cash Flow EUR mil ... ... ... ... ...             ...
Capital Expenditures (As % of Sales) % ... ... ... ... ...             ...
other ratios Unit 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
                         
Effective Tax Rate % ... ... ... ... 0             ...
Total Revenue Growth (5-year average) % ... ... ... ... ...             ...
Total Revenue Growth (10-year average) % ... ... ... ... ... ... ... ... ... ...   ...
valuation Unit 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
                         
Market Capitalisation USD mil ... ... ... ... 23.3             ...
Enterprise Value (EV) USD mil ... ... ... ... 20.2             ...
Number Of Shares mil ... ... ... ... 1.00             ...
Share Price EUR ... ... ... ... 20.3             ...
EV/EBITDA ... ... ... ... 9.77             ...
Price/Earnings (P/E) ... ... ... ... ...             ...
Price/Cash Earnings (P/CE) ... ... ... ... 13.0             ...
P/FCF ... ... ... ... ...             ...
Price/Book Value (P/BV) ... ... ... ... 0.834             ...
Dividend Yield % ... ... ... ... 0             ...
Free Cash Flow Yield % ... ... ... ... ...             ...
Earnings Per Share (EPS) EUR ... ... ... ... 0             ...
Cash Earnings Per Share EUR ... ... ... ... 1.56             ...
Free Cash Flow Per Share EUR ... ... ... ... ...             ...
Book Value Per Share EUR ... ... ... ... 24.3             ...
Dividend Per Share EUR ... ... ... ... 0             ...
EV/Sales ... ... ... ... 0.481             ...
EV/EBIT ... ... ... ... 85.1             ...
EV/Free Cash Flow ... ... ... ... ...             ...
EV/Capital Employed ... ... ... ... 0.490             ...
Earnings Per Share Growth % ... ... ... ... ... ...           ...
Cash Earnings Per Share Growth % ... ... ... ... ...             ...
Book Value Per Share Growth % ... ... ... ... ...             ...

Get all company financials in excel:

Download Sample   $19.99

Saneca's Net Margin remain unchanged yoy at -6.26% in 2019

By Helgi Analytics - November 24, 2020

Saneca Pharmaceuticals made a net profit of EUR -3.60 mil with revenues of EUR 57.5 mil in 2019, up by 0% and up by 60.6%, respectively, compared to the previous year. This translates into a net margin of -6.26%. Historically, between 2018 and 2019, ...

Saneca's Share Price remain unchanged yoy at EUR 20.3 in 2019

By Helgi Analytics - November 24, 2020

Saneca Pharmaceuticals stock traded at EUR 20.3 per share at the end 2019 implying a market capitalization of USD 22.8 mil. Since the end of 2014, stock has appreciated by % implying an annual average growth of % In absolute terms, the value of the company ...

Saneca's P/FCF remain unchanged yoy at -4.82 in 2019

By Helgi Analytics - November 24, 2020

Saneca Pharmaceuticals stock traded at EUR 20.3 per share at the end 2019 translating into a market capitalization of USD 22.8 mil. Since the end of 2014, the stock has appreciated by 0% representing an annual average growth of %. At the end of 2019, the...

Saneca's Net Debt/EBITDA fell 241% yoy to -5.20 in 2019

By Helgi Analytics - November 24, 2020

Saneca Pharmaceuticals's net debt stood at EUR 8.68 mil and accounted for 35.7% of equity at the end of 2019. The ratio is up 46.7 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 35.7% in 2019 and a...

Saneca's Capital Expenditures remain unchanged yoy at EUR 3.69 mil in 2019

By Helgi Analytics - November 24, 2020

Saneca Pharmaceuticals invested a total of EUR 3.69 mil in 2019, down 0% compared to the previous year. Historically, between 2019 - 2019, the company's investments stood at a high of EUR 3.69 mil in 2019 and a low of EUR 3.69 mil in 2019. ...

More News

Saneca Pharmaceuticals is a Slovakia-based pharmaceutical Company that develops and produces pharmaceutical dosage forms, including solid, liquids, gels and creams. The Company (previously known as Slovakofarma) has been merged with Léčiva in 2003 to create Zentiva, taken over in 2009 by Sanofi and a de-merged and acquired by Wood Pharma Holding in 2013. Saneca still generated almost half of total production for Sanofi in 2020. However, increasing part of Company's production should be directed towards active pharmaceutical ingredients (API) and sold to third parties. The share should increase from 24% of total sales in 2020 to almost 33% in 2024, according the management plans.

Finance

Saneca Pharmaceuticals has been growing its sales by a year on average in the last 5 years. EBITDA has grown on average by 100% a year during that time to total of in 2025, or of sales. That’s compared to 8.38% average margin seen in last five years.

The company netted in 2025 implying ROE of and ROCE of . Again, the average figures were 13.1% and 7.50%, respectively when looking at the previous 5 years.

Saneca Pharmaceuticals’s net debt amounted to at the end of 2025, or of equity. When compared to EBITDA, net debt was x,

A PHP Error was encountered

Severity: Warning

Message: A non-numeric value encountered

Filename: src/Environment.php(418) : eval()'d code

Line Number: 269

down when compared to average of 3.90x seen in the last 5 years.

Valuation

Saneca Pharmaceuticals stock traded at per share at the end of 2025 resulting in a market capitalization of . Over the previous five years, stock price fell by 0% or -100% a year on average. The closing price put stock at a 12-month trailing EV/EBITDA of x and price to earnings (PE) of x as of 2025.

More Companies in Slovak Pharmaceutical Sector